Sarici, AhmetErkurt, Mehmet AliKuku, IrfanBahcecioglu, Omer FarukBicim, SoykanKaya, EminBerber, Ilhami2024-08-042024-08-0420221473-05021878-1683https://doi.org/10.1016/j.transci.2021.103296https://hdl.handle.net/11616/100277Objective: In this study, we aimed to report the effectiveness of hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and GATMO scores in predicting overall survival (OS) who underwent autologous stem cell transplantation (ASCT). Material and methods: The data of 263 MM and 204 lymphoma patients who underwent ASCT in the last 11 years were retrospectively analyzed. Results: Neutrophil engraftment time, thrombocyte engraftment time and collected CD34+ cell counts were similar in MM patients with HCT-CI 2 (all p 2 tended to be higher than those with HCT-CI 2 was 51.5 months, the estimated median OS of patients with HCT-CI 2 was 9.5 months (p=0.012). When lymphoma patients were divided into four groups according to their GATMO scores, the OS of the four groups was found to be different from each other (p<0.001). Conclusion: HCT-CI and GATMO scores predict OS in lymphoma patients but not MM patients.eninfo:eu-repo/semantics/closedAccessAutologous stem cell transplantationLymphomaMultiple myelomaHematopoietic cell transplantation-specific comorbidity indexEngraftment timeArticle6113469698210.1016/j.transci.2021.1032962-s2.0-85117695408Q3WOS:000766631700017Q4